Gliclazide-Teva MR modified-release tablets 60 mg blister No. 30

Gliclazide-Teva modified-release tablets are indicated for the treatment of type 2 diabetes mellitus in adults.

Composition

Active ingredient: gliclazide;

1 modified-release tablet contains gliclazide 60 mg;

Excipients: lactose, hypromellose, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate.

Contraindication

Method of application

For oral use.

It is intended for adults only.

The daily dose can vary from 30 to 120 mg per day (1 to 4 tablets of 30 mg per day or half to 2 tablets of 60 mg per day).

The 60 mg pill can be divided into equal parts.

The daily dose should be taken once during breakfast.

Half a tablet or whole tablet(s) should be swallowed whole (NOT crushed or chewed).

If the patient forgets to take the pills, the dose should not be increased the next day.

Like all hypoglycemic agents, Gliclazide-Teva requires individual dose adjustment depending on the patient's response to treatment (blood glucose level, glycosylated hemoglobin HbAlc).

Application features

Pregnant women

Should not be used during pregnancy.

Children

It is not recommended to prescribe.

Drivers

With caution.

Overdose

Overdose of sulfonylurea drugs can cause hypoglycemia.

Symptoms of moderate hypoglycemia (without loss of consciousness and without neurological symptoms) should be corrected by taking carbohydrates (sugar), adjusting the dose of the hypoglycemic drug and / or diet. Close monitoring of the patient should continue until the doctor is sure that the patient is safe.

Side effects

The most common adverse reaction with gliclazide is hypoglycemia. As with other sulfonylureas, gliclazide can cause hypoglycemia with irregular meals and especially if meals are missed. Hypoglycemia may be accompanied by characteristic symptoms such as: headache, intense hunger, nausea, vomiting, fatigue, sleep disturbances, agitation, aggression, decreased concentration and attention, slowed reactions, depression, confusion, visual and speech disorders, aphasia, tremor, paresis, sensory disturbances, dizziness, feeling of weakness, loss of self-control, delirium, convulsions, shallow breathing, bradycardia, drowsiness and loss of consciousness, which can lead to coma and death.

Interaction

Phenylbutazone (for systemic use) enhances the hypoglycemic effect of sulfonylurea drugs (replaces their binding to plasma proteins and / or reduces their excretion). It is advisable to use another anti-inflammatory agent and draw the patient's attention to the need and importance of self-monitoring. If necessary, the dosage is adjusted during and after therapy with the anti-inflammatory agent.

Alcohol increases the risk of hypoglycemic reactions (by inhibiting compensatory reactions), which can lead to hypoglycemic coma. Alcohol and alcohol-containing medications should be avoided.

Storage conditions

The drug does not require special storage conditions.

Keep out of reach of children.

Shelf life - 2 years.